Cerebral Palsy, Dyskinetic, Secondary Dystonia
Conditions
Keywords
High intensity focused ultrasound (HIFU), Pallidotomy
Brief summary
The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
Detailed description
The primary objective of the proposed study is to evaluate the safety of ExAblate Transcranial MRgFUS as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy. The secondary is to assess the impact on Quality of Life of Focused Ultrasound Bilateral and unilateral Pallidotomy for Dyskinetic Cerebral Palsy in Pediatric and Young Adult Subjects. In addition, the impact of bilateral pallidotomy on motor development, pain perception, speech, memory, attention and cognition in these patients will also be assessed.
Interventions
DEVICEFocused Ultrasound Pallidotomy
Use of ExAblate Transcranial MR guided Focused Ultrasound as a tool for creating bilateral or unilateral lesions in the globus pallidus (GPi) in patients with treatment-refractory secondary dystonia due to dyskinetic cerebral palsy
Sponsors
Children's National Research Institute
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to 22 Years
Healthy volunteers
No
Inclusion criteria
* The treating physician has chosen GPi-DBS or pallidotomy for the treatment of the secondary dystonia caused by cerebral palsy in this patient * Patient and/or legal representative, if the patient is underaged or not capable to give consent himself, have chosen pallidotomy as treatment * The consent to participate in the trial of the underaged patient, if he is capable to understand the study requirements, is required * Age at enrolment 8-22 years * Diagnosis of secondary dystonia due to cerebral palsy caused by perinatal hypoxic injury * Anti-dystonic pharmacotherapy insufficient * Stable anti-dystonic medication over the last 30 days * Globus pallidus internus (pars posterior) and thalamus (motor part) intact on MRI (not older than 2 years - if possible) * No fixed severe skeletal deformations with loss of function, which need immediate orthopaedic surgical intervention * Sufficient compliance of the patient or the legal representative if the patient is underaged or not capable to give consent himself to take part in the study * Informed consent to take part in the study from patient and/or legal representative if the patient is underaged or not capable to give consent himself * Patient and/or legal representative if the patient is underaged or not capable to give consent himself, understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed
Exclusion criteria
* Patients with known primary (e.g. DYT1) or idiopathic dystonia * Severe axial hypotonia with total loss of head control (e.g. absence of control at "upper thoracic level" in the SATCo score) (medication effect excluded) * Fixed hemi-dystonia * Severe spasticity in knee- and elbow-flexors and -extensors (Modified Ashworth Scale \>3) * Fixed severe skeletal contractions with loss of function which require immediate orthopaedic surgical intervention * Patients with other severe concurrent neurological disease (e. g. brain tumor, neurodegenerative diseases, trauma etc.) * Condition likely to require use of MRI in the future * Any intracranial abnormality or medical condition that would contraindicate DBS surgery * Any findings in neuropsychological screening assessments that would contraindicate DBS surgery * Any current drug and / or alcohol abuse * Any history of frequent grand-mal seizures without response to anticonvulsive treatment * Any other active implanted device (e.g. Cochlear implant, pacemaker), whether turned on or off, would be allowed provided that they do not interfere with functioning of the device. * The presence of DBS leads due the risks of these ferromagnetic devices in the MRI environment. * A history of neurostimulation intolerance in any area of the body. * Currently on any anticoagulant medications that cannot be discontinued during perioperative period. * Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival \<24 months. * Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days; any other trial participation should be approved by the Principal Investigator. * A female that is breastfeeding or of childbearing potential with a positive urine pregnancy test or - if a person is sexually active - not using sufficient contraception with a Pearl Index of less than 1% including all forms of hormonal contraception ("antibaby-pill", hormonal plaster, NuvaRing®, Implanon®, hormonal depot injections, contraceptive coil), the tubal ligature (female sterilization). Alternatively, the female of child bearing potential is sexually abstinent. * Subjects who have contraindications to anesthesia, in the judgment of the attending anesthesiologist * Subjects who are unwilling or unable to undergo general anesthesia * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the subject or the quality of the data. * Minimum head circumference \< 49cm * Skull Density Ratio (SDR) \<0.40.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of device-related and procedure-related adverse events (AE) | 2 years | Safety will be determined by an evaluation of the incidence and severity of device-related and procedure-related adverse events (AE) from the first treatment day visit through the 24-month post-treatment time point. All AEs will be reported and categorized as related to the device versus the ablation procedure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Burke-Fahn-Marsden-Dystonia Rating Scale movement and disability | 2 years | Assessment of speech and swallowing. Score range: 0-30, 0 indicates complete independence, 30 indicates complete dependence. |
| Family Scale (FaBel) | 2 years | Assessment of the burden for caregivers. Score range: 0-84, 0 indicates no burden, 84 indicates very severe burden. |
| Canadian Occupational Performance Measure (COPM) | 2 years | Assessment of activities of daily living. |
| Gross Motor Function Measure (GMFM-66) | 2 years | Assessment of physical disability. Score range: 0-3, 0 indicates no performance, 3 indicates complete performance. |
| Gross Motor Function Classification System (GMFCS) | 2 years | Degree of physical impairment. Score range: 1-5, 1 indicates no limitations, 5 indicates severe limitations. |
| SF-36 for assessment of quality of life | 2 years | Assessment of quality of life of subject. Score range: 0-100, 0 indicates bad health state, 100 indicates an excellent health state. |
| Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) | 2 years | Assessment of Quality of life of Caregivers and Subject. Score range: 0-100, 0 indicates a bad score, 100 indicates an excellent score. |
| Frenchay Dysarthria Assessment | 2 years | Assessment of speech and swallowing. Score range: |
| Assessment of Cognition | 2 years | Snijders-Oomen-Non-Verbal-Intelligence Test (SON-R) |
| Strengths and Difficulties Questionnaire | 2 years | Assessment of mood and attention. Score range: 0-40, 0 indicates normal, 40 indicates abnormal. |
| Assessment of Attention | 2 years | Attentional Network Test (ANT) |
| Assessment of cognition | 2 years | Non-Verbal-Learning Test (NVLT) |
| Wong Baker Faces | 2 years | Assessment of pain. Score range; 0-10, 0 indicates no pain, 10 indicates worst pain. |
| Tardieu Scale | 2 years | Assessment of the severity of spasticity. Score range: 0-5, 0 indicates no resistance, 5 indicates no movement. |
| Dyskinesia Impairment Scale (DIS) | 2 years | Assessment of the severity of chorea and dystonia. Score range: 0-576, 0 indicates no dystonia, 576 indicates very severe dystonia. |
| Barry Albright Dystonia Scale | 2 years | Score range: 0-32, 0 indicates no dystonia, 32 indicates severe dystonia. |
Countries
United States
Contacts
CONTACTChima Oluigbo, MD
CONTACTSaige Teti
PRINCIPAL_INVESTIGATORChima Oluigbo, MD
Children's National Hospital, Washington, DC
Outcome results
None listed